Chimeric antigen receptor (CAR) T cells have emerged as a promising treatment for patients with advanced B-cell cancers. However, widespread application of the therapy is currently limited by potentially life-threatening toxicities due to a lack of control of the highly potent transfused cells. Researchers have therefore developed several regulatory mechanisms in order to control CAR T cells in vivo. Clinical adoption of these control systems will depend on several factors, including the need for temporal and spatial control, the immunogenicity of the requisite components as well as whether the system allows reversible control or induces permanent elimination. Here we describe currently available and emerging control methods and review their function, advantages, and limitations.

嵌合抗原受体（CAR）T细胞已成为晚期B细胞癌患者的有前途的治疗方法。但是，由于缺乏对高效输血细胞的控制，目前该疗法的广泛应用受到潜在威胁生命的毒性的限制。因此，研究人员开发了几种调控机制来控制CAR T细胞体内。这些控制系统的临床采用将取决于几个因素，包括对时间和空间控制的需要，必需成分的免疫原性以及系统是否允许可逆控制或引起永久消除。在这里，我们描述了当前可用的和新兴的控制方法，并回顾了它们的功能，优点和局限性。